finanzen.net
22.07.2019 06:37
Bewerten
(0)

InvaGen (a Cipla Subsidiary) Receives Final Approval for Generic Version of Pfizer's Lyrica® (Pregabalin Capsules, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg)

NEW YORK and MUMBAI, India, July 22, 2019 /PRNewswire/ -- InvaGen Pharmaceuticals, Inc. ("InvaGen"), a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as "Cipla") announced the receipt of final approval for its Abbreviated New Drug Application (ANDA) for Pregabalin Capsules, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg from the United States Food and Drug Administration (US FDA).

InvaGen's Pregabalin Capsules, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg is AB-rated generic therapeutic equivalent version of Pfizer's Lyrica®. Pregabalin capsules are indicated for:

  • Management of neuropathic pain associated with diabetic peripheral neuropathy
  • Management of postherpetic neuralgia
  • Adjunctive therapy for the treatment of partial onset seizures in patients 17 years of age and older
  • Management of fibromyalgia
  • Management of neuropathic pain associated with spinal cord injury

According to IQVIA (IMS Health), Lyrica® had US sales of approximately $5.4 Billion for the 12-month period ending March 2019. The product is available for shipping immediately.

About Cipla:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Mar'19), 3rd largest in the pharma private market in South Africa (IQVIA MAT Mar'19), and is among the most dispensed generic players in the US. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.

 

Cision View original content:http://www.prnewswire.com/news-releases/invagen-a-cipla-subsidiary-receives-final-approval-for-generic-version-of-pfizers-lyrica-pregabalin-capsules-25mg-50mg-75mg-100mg-150mg-200mg-225mg-300mg-300888411.html

SOURCE Cipla

Werbung
Werbung
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX gewinnt deutlich -- Asiens Börsen legen zu -- BASF will Dividende perspektivisch anheben -- Trump: Apple wird "riesige Summen" in den USA investieren -- Vapiano-Chef kündigt Rücktritt an

1&1 Drillisch-Aktie gleicht Verluste aus und legt weiter zu. Handelskrieg macht Chinesen Appetit auf Kryptowährungen. Grand City Properties bekräftigt Jahresziele. US-Wirtschaftsberater Kudlow: "Es ist keine Rezession in Sichtweite". ElringKlinger plant Einsparungen in Millionenhöhe.

Die 5 beliebtesten Top-Rankings


Diese Aktien hat Warren Buffett im Depot
Einige Änderungen unter den Top-Positionen
Die wertvollsten Fußballvereine der Welt 2019
Welcher Club ist am wertvollsten?
Promis
Diese Sternchen haben ihren eigenen Aktien-Index
Die erfolgreichsten Kinofilme der letzten 25 Jahre
Welche Titel knackten die Milliardenmarke an den Kinokassen?
Apps & Social Media: Die wertvollsten Marken der Welt
Welche Marke macht das Rennen?
mehr Top Rankings

Umfrage

Die Marktturbulenzen nehmen zu. Investieren Sie nun vermehrt in "sichere Häfen"?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Braas Monier Building Group S.A.BMSA01
MTU Aero Engines AG Em 2017A2G83P
XING (New Work)XNG888
Deutsche Bank AG514000
Wirecard AG747206
Daimler AG710000
Microsoft Corp.870747
BASFBASF11
BayerBAY001
NEL ASAA0B733
Apple Inc.865985
Amazon906866
EVOTEC SE566480
Scout24 AGA12DM8
Allianz840400